Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients ...

Mission: to design our clinical trials to be inclusive and more representative of the populations who are most likely to benefit from our medicines. Vision: we envision a future where inclusivity is ...

For over 100 years, we have been protecting the health of millions. But an additional 1.5 million lives could be saved each year with improved vaccination coverage (1). We are often unaware of the ...

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain ...

Les résultats du troisième trimestre 2024 seront commentés par le management au cours d'un webcast audio en direct avec la communauté financière. La présentation sera suivie d'une session de questions ...

Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement ...

We want to improve the lives of millions of people who don’t have access to the help they need. To do that, we’re expanding our health-system partnerships at local, regional, and global levels.

We’re using AI to chase the miracles of science by accelerating drug discovery, enhancing clinical trial design, and improving the manufacturing and supply of medicines and vaccines to get them to ...